CSL Behring’s Hizentra (R) (Immune Globulin Subcutaneous [Human] 20% Liquid) is the most prescribed SCIg treatment and the first and only SCIg treatment approved for CIDP. In 2020, as part of ...

(Bloomberg) -- Australian biotech group CSL Ltd. has begun enrolling US patients in a late-stage study to test a ...

Aim: To report the interesting case of a patient with common variable immune deficiency disease who demonstrated varied responses to intravenous (IV) and subcutaneous (SC) immunoglobulin (Ig ...